Fluorescence imaging to improve surgery for liver cancer
An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma
This study is testing a new imaging technique during liver cancer surgery to see if it helps doctors find tumors more accurately and safely.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Chinese Academy of Sciences Government |
| Locations | 2 sites (Zhuhai, Guangdong and 1 other locations) |
| Trial ID | NCT05047510 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of intraoperative fluorescence imaging that targets GPC3 to enhance the surgical accuracy in patients with hepatocellular carcinoma. The approach involves using a novel near-infrared fluorescence molecular imaging technique combined with a GPC-3 targeted fluorophore to increase the detection rate of liver tumors during surgery. The study aims to validate the safety and effectiveness of this imaging method for clinical application in hepatectomy procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 diagnosed with hepatocellular carcinoma who are scheduled for hepatectomy and have liver function classified as Child-Pugh A or B.
Not a fit: Patients with other malignant tumors, severe organ dysfunction, or those unable to tolerate surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to more accurate surgical removal of liver tumors, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using fluorescence imaging for tumor detection, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have been diagnosed with hepatocellular carcinoma. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. GPC-3 was validated highly expressed preoperatively. 5. Aged 18 to 75, and the expected lifetime is longer than 6 months. 6. Approved to sign the informed consent. Exclusion Criteria: 1. Allergic to IRDye800. 2. Enrolled in other trials in the past 3 months. 3. Another malignant tumor was found. 4. Undesirable function of heart, lung, kidney, or any other organs. 5. Unable to tolerate a hepatectomy. 6. The researchers considered inappropriate to be included.
Where this trial is running
Zhuhai, Guangdong and 1 other locations
- Zhuhai People's Hospital — Zhuhai, Guangdong, China (Recruiting)
- The Affiliated Hospital of Southwest Medical University — Luzhou, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Zeyu Zhang, Ph.D.
- Email: zhangzeyu@fingerpass.net.cn
- Phone: 86-18201082715
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.